Attached files
| file | filename |
|---|---|
| 10-K - 10-K - CytomX Therapeutics, Inc. | ctmx-10k_20161231.htm |
| EX-32.1 - EX-32.1 - CytomX Therapeutics, Inc. | ctmx-ex321_9.htm |
| EX-31.2 - EX-31.2 - CytomX Therapeutics, Inc. | ctmx-ex312_8.htm |
| EX-31.1 - EX-31.1 - CytomX Therapeutics, Inc. | ctmx-ex311_7.htm |
| EX-10.8(C) - EX-10.8(C) - CytomX Therapeutics, Inc. | ctmx-ex108c_889.htm |
| EX-10.7(C) - EX-10.7(C) - CytomX Therapeutics, Inc. | ctmx-ex107c_890.htm |
| EX-10.6(C) - EX-10.6(C) - CytomX Therapeutics, Inc. | ctmx-ex106c_891.htm |
| EX-10.5(C) - EX-10.5(C) - CytomX Therapeutics, Inc. | ctmx-ex105c_888.htm |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-214418) and Form S-8 (Nos. 333-207694, 333-209992 and 333-215795) of CytomX Therapeutics, Inc. of our report dated March 2, 2017 relating to the financial statements, which appears in this Form 10‑K.
/s/ PricewaterhouseCoopers LLP
San Jose, California
March 2, 2017